New antibiotics targeting drug-resistant Gram-negative bacterial infections
Official title: Novel Biamyxins targeting multidrug resistant Gram-negative bacterial infections
Funded at State University of New York at Buffalo · NIH-10859228 · Data updated 2026-11-12
This study is working on a new type of antibiotic called biamyxins to help fight tough infections caused by bacteria that don't respond to regular treatments, especially for patients dealing with serious healthcare-related infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project start | July 2, 2024 |
| Project end | June 30, 2029 |
| Funding year | 2024 |
| Award (this year) | $802,798 |
| NIH project number | 1R01AI182297-01 |
| Project ID | NIH-10859228 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with infections caused by multidrug-resistant Gram-negative bacteria, particularly those who have not responded to existing antibiotics.
✕Less likely to help
Patients with infections caused by non-Gram-negative bacteria or those who are not infected may not receive any benefit from this research.
What this research studies
This research focuses on developing a new class of antibiotics called biamyxins, which are designed to combat multidrug-resistant Gram-negative bacteria that cause serious healthcare-associated infections. The approach involves creating semisynthetic peptides that bind to the outer membrane of these bacteria, enhancing their effectiveness against strains that are resistant to current treatments. By targeting specific pathogens like Acinetobacter baumannii, this research aims to provide a broader spectrum of antimicrobial activity. Patients with infections caused by these resistant bacteria may benefit from the novel treatments being developed.
Why it matters
Potential benefit: If successful, this research could lead to effective new treatments for patients suffering from difficult-to-treat bacterial infections.
How similar studies have gone: Other research has shown promise in developing new antibiotics for resistant bacteria, indicating that this approach could be a viable solution.
Where this research is happening
-
State University of New York at Buffalo
Amherst, United States Active
Researchers
- Principal investigator: Zhao, Yanan — State University of New York at Buffalo
- Study coordinator: Zhao, Yanan
Related research
Other NIH-funded projects on the same topics.
-
Host-Directed Orynotide for MDR Gram-Negative Infections
A new drug candidate called Orynotide MTD12813 is being developed to treat serious drug-resistant infections caused by bacteria like Acinetobacter and Enterobacteriaceae.
-
Genomic-informed, low-cost, portable test to rapidly identify drug-resistant bacterial infections
A portable, affordable test called BADLOCK could quickly identify bacteria and resistance genes from blood samples to help treat drug-resistant infections.
-
Novel BMX antibiotics for tough Gram-negative infections
A new class of BMX antibiotics is being developed to fight hard-to-treat Gram-negative infections like Acinetobacter baumannii in patients.
-
Center to speed up antibacterial drugs for hard-to-treat infections
A national center at Hackensack University Medical Center aims to speed up the development of new antibiotics to fight high-threat, drug-resistant bacterial infections.
-
Center accelerating antibiotic development for high-threat bacterial infections
A research center in academia–industry collaboration is speeding up the development of new antibiotics to fight highly resistant bacteria so patients have better treatment options.
-
PACC1 in the body’s defense against bacterial infections and sepsis
A study exploring how a protein called PACC1 helps immune cells fight bacteria and prevent sepsis, with potential benefits for people at risk of severe infections.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.